1. Circ Cardiovasc Interv
Outcomes After Unrestricted Use of Everolimus-Eluting and Sirolimus-Eluting Stents in Routine Clinical Practice
by Duk-Woo Park, Young-Hak Kim, Hae-Geun Song, Jung-Min Ahn, Won-Jang Kim, Jong-Young Lee, Soo-Jin Kang, Seung-Whan Lee, Cheol Whan Lee, Seong-Wook Park, Sung-Cheol Yun, Sung Ho Her, Seung Ho Hur, Jin Sik Park, Myeong-Kon Kim, Yun Seok Choi, Hyun Sook Kim, Jang-Hyun Cho, Sang Gon Lee, Yong Whi Park, Myung-Ho Jeong, Bong Ki Lee, Nae-Hee Lee, Do-Sun Lim, Junghan Yoon, Ki Bae Seung, Won-Yong Shin, Seung-Woon Rha, Kee-Sik Kim, Seung-Jea Tahk, Byoung Eun Park, Taehoon Ahn, Joo-Young Yang, Yong Seok Jeong, Jay-Hyun Rhew, and Seung-Jung Park
Circ Cardiovasc Interv
Volume 5(3):
June 19, 2012
Copyright © American Heart Association, Inc. All rights reserved.

2. Cumulative incidence of the primary end point and selected secondary end points, according to stent group.
Cumulative incidence of the primary end point and selected secondary end points, according to stent group. Cumulative-incidence curves are shown for the primary end point of death, nonfatal myocardial infarction (MI), or TVR (A), death or nonfatal MI(B), TVR (C), and definite or probable stent thrombosis (D). Probability values were calculated with the use of the log-rank test. EES indicates everolimus-eluting stent; SES, sirolimus-eluting stent; TVR, target-vessel revascularization.
Duk-Woo Park et al. Circ Cardiovasc Interv. 2012;5:
Copyright © American Heart Association, Inc. All rights reserved.